187 related articles for article (PubMed ID: 35895234)
21. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
[TBL] [Abstract][Full Text] [Related]
22. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
[TBL] [Abstract][Full Text] [Related]
23. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.
Tamaki N; Kurosaki M; Yasui Y; Mori N; Tsuji K; Hasebe C; Joko K; Akahane T; Furuta K; Kobashi H; Kimura H; Yagisawa H; Marusawa H; Kondo M; Kojima Y; Yoshida H; Uchida Y; Loomba R; Izumi N
Clin Infect Dis; 2021 Nov; 73(9):e3349-e3354. PubMed ID: 33544129
[TBL] [Abstract][Full Text] [Related]
24. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
[TBL] [Abstract][Full Text] [Related]
25. Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus.
Kuo YH; Kee KM; Hung CH; Lu SN; Hu TH; Chen CH; Wang JH
Kaohsiung J Med Sci; 2022 Mar; 38(3):268-276. PubMed ID: 34687140
[TBL] [Abstract][Full Text] [Related]
26. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
[TBL] [Abstract][Full Text] [Related]
27. Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.
Nakai M; Yamamoto Y; Baba M; Suda G; Kubo A; Tokuchi Y; Kitagataya T; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Sho T; Morikawa K; Ogawa K; Furuya K; Sakamoto N
Sci Rep; 2022 Jan; 12(1):1449. PubMed ID: 35087141
[TBL] [Abstract][Full Text] [Related]
28. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
29. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication.
Kumada T; Toyoda H; Yasuda S; Tada T; Tanaka J
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e513-e521. PubMed ID: 33852513
[TBL] [Abstract][Full Text] [Related]
31. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients.
Wang HM; Hung CH; Lu SN; Chen CH; Lee CM; Hu TH; Wang JH
Liver Int; 2013 May; 33(5):756-61. PubMed ID: 23405889
[TBL] [Abstract][Full Text] [Related]
32. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
Sanduzzi-Zamparelli M; Mariño Z; Lens S; Sapena V; Iserte G; Pla A; Granel N; Bartres C; Llarch N; Vilana R; Nuñez I; Darnell A; Belmonte E; García-Criado A; Díaz A; Muñoz-Martinez S; Ayuso C; Bianchi L; Fuster-Anglada C; Rimola J; Forner A; Torres F; Bruix J; Forns X; Reig M
J Hepatol; 2022 Apr; 76(4):874-882. PubMed ID: 34856322
[TBL] [Abstract][Full Text] [Related]
33. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K
J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686
[TBL] [Abstract][Full Text] [Related]
34. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
35. Dynamic Changes in Non-Invasive Markers of Liver Fibrosis Are Predictors of Liver Events after SVR in HCV Patients.
Fernández-Alvarez P; Guerra-Veloz MF; Vilches-Arenas A; Cordero-Ruíz P; Bellido-Muñoz F; Caunedo-Alvarez A; Carmona-Soria I
Viruses; 2023 May; 15(6):. PubMed ID: 37376551
[No Abstract] [Full Text] [Related]
36. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
38. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
Roche B; Coilly A; Duclos-Vallee JC; Samuel D
Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
[TBL] [Abstract][Full Text] [Related]
39. Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy.
Narita Y; Genda T; Tsuzura H; Sato S; Kanemitsu Y; Ishikawa S; Kikuchi T; Hirano K; Iijima K; Wada R; Ichida T
J Gastroenterol Hepatol; 2014 Jan; 29(1):137-43. PubMed ID: 24117602
[TBL] [Abstract][Full Text] [Related]
40. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
